Eth Zurich

Labopharm Inc.

Universitéde Montreal

Universitât Bern

Valorisation-Recherche, Limited Partnership

University of California

Evonik Roehm Gmbh

Roehm Gmbh & Co Kg

Ethypharm, Inc.

Labopharm Europe Limited

Labopharm (Barbados) Limited

Versantis Ag

Dicronis Sagl

Valorization-Recherche Limited Partnership

Evonik Rohm Gmbh

Jean-Christophe Leroux

Mattias E Ivarsson

Bastien Castagner

Maxime Ranger

Hans-Ulrich Petereit

Klaus Schultes

Christian Meier

Vincent Forster

Andreas Pasch

Gisbert Schneider

Simon Matoori

Marie-Andree Yessine

Mohamad Nasser Eddine

Anna Pratsinis

Demetrios P Papahadjopoulos

Vinayak Sant

Michael Detmar

Bhalchandra Shripad Lele

Anne-Claude Couffin-Hoarau

Anna Kletzmayr

Olivier Meyer

Didier Hoarau

Olha Voznyuk Wuerthinger

Makoto Kuro-o

Hirosaka Hayashi

Amina Souad Benahmed

Valentina Agostoni

Pascal Delmas

Doroth&eacute;e Le Garrec

Meriam Kabbaj

Guillaume Bastiat

Steven Proulx

Davide Brambilla

Aaron Christoph Schmidt

Marie Andree Yessine

Marie-Andrée Yessine

The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.

Transmembrane pH-gradient polymersomes for the quantification of ammonia in body fluids

The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Inositol derivatives for use in pathological crystallization

The invention relates to a method for preparing transmembrane pH-gradient vesicles. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l. The matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, which differs from the basic or acidic buffer in pH value.

Method for preparing transmembrane pH-gradient vesicles

The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

The present invention provides polymersomes comprising non-biodegradable amphiphilic block-copolymers and their enteral (e.g., oral) or topical use in the treatment of an ammonia or ammonia methylated analog-associated disease or disorder or symptom thereof (e.g., hyperammonemia or trimethylaminuria). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS/PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid. It also provides a method of making the polymersome comprising mixing the copolymer-containing organic solvent phase with an aqueous phase containing the acid.

Transmembrane pH-gradient polymersomes and their use in the scavenging of ammonia and its methylated analogs

This invention describes compositions comprising indocyanine green and poly(N-vinylpyrrolidone) and methods of making the same as well as applications thereof for diagnostic and therapeutic uses. One of those applications is the structural and functional assessment of the lymphatic system by fluorescence imaging.

Compositions for circulatory system visualization

The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

Liposome composition for use in peritoneal dialysis

The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated withinfection.

4,6-di-(O-thiophosphate)-inositol-1,2,3,5-tetra-O-sulfate forinfection

A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.

Pharmaceutical compositions comprising polymeric binders with non-hydrolysable covalent bonds and their use in treating celiac disease

The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO, OPSOor OSO; Ris a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by

Pharmaceutical compounds for use in the therapy of clostridium difficile infection

The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO, OPSOor OSO; Rcomprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO, OPSO,or OSO; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by

[object Object]

Pharmaceutical compositions comprising polymeric binders with non-hydrolysable their use in treating celiac disease

A pH-sensitive polymer which has cytotoxic or membranolytic properties at pH values below pH 6.5. Carriers for natural or synthetic biomolecules or active pharmaceutical ingredients using such a pH-sensitive polymer.

pH-sensitive polymer

Growing community of inventors

Montreal, Canada

Jean-Christophe Leroux